FREELINE
Live / Registered — Registered (as of 04 Feb 2020)
What this means for you
Registered since 04 Feb 2020. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79252849
- Registration number
- 5974485
- Mark type
- Word mark
- Filed
- 19 Nov 2018
- Published for opposition
- 19 Nov 2019
- Registered
- 04 Feb 2020
- Attorney of record
- Samantha M. Quimby
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical, medical and veterinary preparations for prevention, amelioration or treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases; pharmaceutical, medical and clinical preparations for therapeutic or prophylactic purposes in connection with blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases; pharmaceutical, medical and clinical preparations for use in treatment, amelioration or prophylaxis of genetic or inherited or non-infectious diseases or disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders or cancers; pharmaceutical, medical and clinical preparations for treatment, amelioration or prophylaxis of chronic or systemic disease, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders or cancers; pharmaceutical, medical and clinical preparations for use in gene therapy for prevention, amelioration or treatment of disorders, namely of blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases; pharmaceutical, medical and clinical preparations for liver-targeted viral gene therapy; genetic medicines for prevention, amelioration or treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious disease; preparations for therapeutic delivery of nucleic acids; viral or nucleic acid vectors for therapeutic or prophylactic purposes or preparations containing such vectors; adeno-associated viral gene therapy preparations for prevention, amelioration or treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases
- Class 040 — Treatment of materials: Pharmaceutical manufacturing and processing to the order and specification of others; biotechnological or biopharmaceutical manufacturing and processing to the order and specification of others; viral vector production to the order and specification of others; gene therapy manufacturing to the order and specification of others; pharmaceutical formulation to the order and specification of others
Owner
Prior registrations
Prosecution history
- 04 Feb 2025 — COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
- 04 Feb 2023 — CHANGE OF NAME/ADDRESS REC'D FROM IB
- 06 Aug 2022 — NEW REPRESENTATIVE AT IB RECEIVED
- 05 Jun 2020 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 18 May 2020 — FINAL DISPOSITION NOTICE SENT TO IB
- 18 May 2020 — FINAL DISPOSITION PROCESSED
- 04 May 2020 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 04 Feb 2020 — REGISTERED-PRINCIPAL REGISTER
- 19 Nov 2019 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 19 Nov 2019 — PUBLISHED FOR OPPOSITION
- 15 Nov 2019 — NOTIFICATION PROCESSED BY IB
- 30 Oct 2019 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
- 30 Oct 2019 — NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
- 30 Oct 2019 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 17 Oct 2019 — ASSIGNED TO LIE